Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03310879 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6

StatusRecruiting
PhasePhase 2
Started2017-11-21
View on ClinicalTrials.gov ↗

Amendment history

2026-04-24
Study Status, Oversight, Outcome Measures v16
Primary completion date2026-04-01→2027-01-01
Completion date2026-09-30→2027-09-30
Secondary endpoints2 entries, revised
ToxicityAdverse events by CTCAE 4.03
2025-08-26
Study Identification, Study Status, Oversight v15
Primary completion date2025-09-01→2026-04-01
Completion date2026-04-30→2026-09-30
Study titlerevised
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-typeType Cyclins or Amplification of CDK4 or CDK6
2025-01-23
Study Status v14
Primary completion date2024-12-31→2025-09-01
Completion date2025-04-30→2026-04-30
2024-02-02
Study Status, Contacts/Locations v13
Primary completion date2024-06-01→2024-12-31
2023-07-09
Study Status v12
Primary completion date2023-06-01→2024-06-01
Show 11 earlier versions
2023-01-09
Study Status v11
Re-verified, no change to tracked fields
2022-01-18
Study Status v10
Primary completion date2022-06-01→2023-06-01
2021-06-01
Study Status v9
Primary completion date2021-04-30→2022-06-01
2020-12-01
6 amendments v3-v8
6 re-verifications since 2018-06-29, no change to tracked fields
2017-11-30
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2017-11-15→confirmed 2017-11-21
Study sitesdetails revised at 1 of 1 site
2017-11-02
Study Identification, Study Status, Outcome Measures v1
Start date2017-10-31→2017-11-15
Secondary endpointsdetails revised at 2 of 2 entries
Study title-25 characters
A Phase II Study of the CDK4/6 Inhibitor Abemaciclib in Patients With Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6
2017-10-11
Original filing
This research study is studying a targeted therapy as a possible treatment for cancer abnormality in one of the following genes: CCND1, CCND2, CCND3, CDK4, or CDK6. The drug involved in this study is: -Abemaciclib
Trial Details
NCT Number NCT03310879
Lead Sponsor Dana-Farber Cancer Institute
Collaborators: Eli Lilly and Company
Conditions Cancer
Enrollment 38 participants
Start Date 2017-11-21
Primary Completion 2027-01-01 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-29